Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8583 Monotherapy in ART-Naïve HIV-1
NCT03552536Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-8583 in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants With at Least One Adverse Event, Number of Participants Who Discontinued Study Due to an AE at Day 1 and 1 more. Started Oct 2018; status: completed.
02
Drugs
mk-8583
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03552536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552536.